Chris Shibutani
Stock Analyst at Goldman Sachs
(3.31)
# 869
Out of 4,818 analysts
99
Total ratings
51.92%
Success rate
0.37%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $33.16 | +201.57% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $1.42 | +111.27% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $9.73 | +54.16% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $27.15 | +17.86% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $114.83 | +19.31% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $13.01 | +153.65% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $293.46 | +2.91% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $31.69 | +60.93% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $155.38 | -0.24% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $5.06 | -20.95% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $11.49 | +74.06% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $829.42 | -12.83% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $25.46 | +2.12% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $103.22 | +48.23% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $177.05 | -2.29% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.69 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $48.53 | +42.18% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $18.39 | -29.29% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $37.44 | -38.57% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $1.16 | +4,210.34% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $30.70 | +69.38% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $22.39 | +167.98% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $8.71 | +106.66% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.49 | +1,040.94% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.28 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.85 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.03 | - | 4 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $28.90 | - | 3 | May 2, 2017 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $33.16
Upside: +201.57%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $1.42
Upside: +111.27%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $9.73
Upside: +54.16%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $27.15
Upside: +17.86%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $114.83
Upside: +19.31%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $13.01
Upside: +153.65%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $293.46
Upside: +2.91%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $31.69
Upside: +60.93%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $155.38
Upside: -0.24%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $5.06
Upside: -20.95%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $11.49
Upside: +74.06%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $829.42
Upside: -12.83%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $25.46
Upside: +2.12%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $103.22
Upside: +48.23%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $177.05
Upside: -2.29%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.69
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $48.53
Upside: +42.18%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $18.39
Upside: -29.29%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $37.44
Upside: -38.57%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $1.16
Upside: +4,210.34%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $30.70
Upside: +69.38%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $22.39
Upside: +167.98%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $8.71
Upside: +106.66%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $1.49
Upside: +1,040.94%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.28
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $4.85
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.03
Upside: -
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $28.90
Upside: -